Acetylcholine-induced coronary spasm in patients with unobstructed coronary arteries is associated with elevated concentrations of soluble CD40 ligand and high-sensitivity C-reactive protein
暂无分享,去创建一个
J. Kaski | A. Carro | U. Sechtem | D. Gaze | G. Borgulya | P. Ong | A. Athanasiadis | D. Ratge | T. Schäufele
[1] B. Ahmed. New insights into the pathophysiology, classification, and diagnosis of coronary microvascular dysfunction. , 2014, Coronary artery disease.
[2] F. Crea,et al. Coronary microvascular dysfunction in patients without myocardial diseases and obstructive atherosclerosis , 2014 .
[3] J. Kaski,et al. Clinical Usefulness, Angiographic Characteristics, and Safety Evaluation of Intracoronary Acetylcholine Provocation Testing Among 921 Consecutive White Patients With Unobstructed Coronary Arteries , 2014, Circulation.
[4] L. Ayers,et al. Increased myocardial prevalence of C-reactive protein in human coronary heart disease: direct effects on microvessel density and endothelial cell survival. , 2012, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[5] J. Kaski,et al. Obesity, Inflammation and Brachial Artery Flow-Mediated Dilatation: Therapeutic Targets in Patients with Microvascular Angina (Cardiac Syndrome X) , 2012, Cardiovascular Drugs and Therapy.
[6] M. Kimura,et al. In Vivo Assessment of Ergonovine-Induced Coronary Artery Spasm by 64-Slice Multislice Computed Tomography , 2012, Circulation. Cardiovascular imaging.
[7] J. Kaski,et al. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). , 2012, Journal of the American College of Cardiology.
[8] F. Crea,et al. Contemporary Reviews in Cardiovascular Medicine Mechanisms of Coronary Artery Spasm , 2011 .
[9] J. Kaski,et al. Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X. , 2010, Atherosclerosis.
[10] D. Granger,et al. Microvascular Responses to Cardiovascular Risk Factors , 2010, Microcirculation.
[11] T. Michel,et al. Cellular signaling and NO production , 2010, Pflügers Archiv - European Journal of Physiology.
[12] M. Rubens,et al. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. , 2009, European heart journal.
[13] T. Lüscher,et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study , 2009, European heart journal.
[14] U. Sechtem,et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. , 2008, Journal of the American College of Cardiology.
[15] M. Sabatine,et al. Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome , 2007, Circulation.
[16] R. de Caterina,et al. Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update , 2007, Journal of internal medicine.
[17] J. Kaski,et al. Microvascular dysfunction in cardiac syndrome X: the role of inflammation , 2006, Canadian Medical Association Journal.
[18] N. Yang,et al. Relation of high-sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease. , 2005, The American journal of cardiology.
[19] H. Turhan,et al. Increased Levels of Soluble Adhesion Molecules E-Selectin and P-Selectin in Patients with Cardiac Syndrome X , 2005, Angiology.
[20] J. Kaski,et al. Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris , 2004, Circulation.
[21] A. Takeshita,et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. , 2004, Journal of molecular and cellular cardiology.
[22] K. Chayama,et al. Relation between C reactive protein concentrations and coronary microvascular endothelial function , 2004, Heart.
[23] J. Kaski,et al. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. , 2003, Journal of the American College of Cardiology.
[24] Hiroaki Shimokawa,et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. , 2003, Journal of the American College of Cardiology.
[25] H. Fukuda,et al. Clinical and angiographical characteristics of acetylcholine- induced spasm: relationship to dose of intracoronary injection of acetylcholine , 2002, Coronary artery disease.
[26] A. Takeshita,et al. Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Patients With Vasospastic Angina , 2002, Circulation.
[27] D. Tousoulis,et al. Vascular cell adhesion molecule‐1 and intercellular adhesion molecule‐1 serum level in patients with chest pain and normal coronary arteries (syndrome X) , 2001, Clinical cardiology.
[28] H. Bøtker,et al. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. , 1999, Journal of the American College of Cardiology.
[29] A. Takeshita,et al. Angina pectoris caused by coronary microvascular spasm , 1998, The Lancet.
[30] K. Miwa,et al. Soluble E-selectin, ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina. , 1997, Cardiovascular research.
[31] R. Frye,et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. , 1975, Circulation.